ABSTRACT
Background The COVID-19 pandemic has altered the conditions leading people to smoke. Multiple studies have examined changes in population levels of smoking at the start of the pandemic. However, conclusions remain mixed due to the high proportion of studies with poor methods and short follow-up periods.
Methods This study used longitudinal data from the UKHLS COVID-19 study to derive smoking trajectories among 4,130 UK adults aged 35-64 across four time points over the first year of the pandemic (2018-19, April 2020, September 2020, and January 2021). Random-effects models were used to examine subject-specific changes across time points.
Results Between the pre-pandemic estimate and January 2021, there was a significant decline in smoking from 14.8% to 13.1% (PR = 0.89, 95%CI 0.83-0.95). The number of cigarettes smoked per day among smokers increased in April 2020 (B = 0.5, 95%CI 0.0, 1.0) and September 2020 (B = 1.0, 95%CI 0.4, 1.5), but declined back to pre-pandemic levels in January 2021 (B = 0.3, 95%CI -0.3, 0.8). These changes did not vary by sex, ethnicity, relationship status, education, occupation, or household income.
Conclusion Among UK adults aged 35-64, there has been a slight decrease in smoking which was maintained up to January 2021. Whereas there was an increase in cigarette consumption among smokers at the start of the pandemic, this was no longer observable in January 2021. The findings support the argument that the first year of the pandemic is unlikely to have had a negative effect of most middle-aged adult smokers’ trajectory.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
TG is funded through a Banting Postdoctoral Fellowship by the Canadian Institutes for Health Research (CIHR). They were not involved in the decision to write this report or submit it.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Source data were openly available before the start of the study. The UKHLS main and COVID-19 datasets can be accessed from the UK Data Service.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The UKHLS main and COVID-19 datasets can be accessed from the UK Data Service.
